Grant of Options

6 March 2015

Rex Bionics plc

("Rex Bionics" or the "Company")

Grant of Options

Rex Bionics plc (AIM: RXB), the pioneer of the REX Robot technology that enhances the mobility of wheelchair users, today announces that on 24 February 2015 the Board of the Company ratified the grant to Crispin Simon, Chief Executive Officer, of options ("Options") over 178,616 ordinary shares of one pound each in the capital of the Company ("Ordinary Shares") at an exercise price of £1.655 per Ordinary Share, with an effective date of grant of 20 November 2014. The Options represent in aggregate 1.25 per cent of the existing issued share capital.

The Options are issued under the Company's Share Option Plan and vest over a three year period, subject to achievement of performance conditions established by the Company's Remuneration Committee. Vested Options are exercisable until 19 November 2024.

, Following the grant of the Options, the interests of Mr Simon in the Company are as follows:

Ends 

For further information please contact:

Rex Bionics Plc

Crispin Simon, Chief Executive Officer

+44 (0) 781 086 6386

Peter Worrall, Chief Financial Officer

+44 (0) 142 864 5416

Stifel Nicolaus Europe Limited (NOMAD and Broker)

Jonathan Senior/Giles Balleny

+44 (0) 20 7710 7600

Consilium Strategic Communications

Mary-Jane Elliott / Jessica Hodgson / Chris Welsh / Lindsey Neville

[email protected]

+44 (0) 203 709 5700

About Rex Bionics plc

Rex Bionics (AIM: RXB) is the AIM-listed pioneer of the REX Robot that enhances the mobility of wheel-chair users. Founded in Auckland, New Zealand by two robotics engineers with first-hand experience of wheelchair users and their needs, Rex Bionics is working with physiotherapists to develop the practice of Robot-Assisted Physiotherapy (RAP). In a session of RAP, REX lifts patients from a sitting position into a robot-supported standing position, allowing them to take part in a set of supported walking and stretching exercises, designed by specialist physiotherapists. 

Wheelchair users are at risk of developing numerous medical complications from extended periods of sitting. By enabling them to spend more time standing, walking and exercising, REX may offer significant health benefits, including improved sleep, cardiovascular performance, maintenance of joint range, and a reduction in common abdominal problems and prescription drug use. A programme of clinical trials is now under way to evaluate these potential benefits. 

REX is used by people with complete spinal cord injury, as well as people who have suffered a stroke or other traumatic brain injury; and people with multiple sclerosis and muscular dystrophy. REX P, for use in the home, enables users to walk and stand with their hands free - providing more work and recreation options. 

In May 2014, Rex Bionics joined AIM with a fundraising of £10 million (gross) to scale up production, distribution and marketing internationally, in order to support growing demand for both REX products as well as developing the next generation of REX devices, REX 3.

REX is not approved for At-Home use in the United States of America.